{"product_id":"matos-masters-in-thoracic-oncology-summit-2023","title":"MATOS Masters in Thoracic Oncology Summit 2023","description":"\u003cheader class=\"section__headings section__headings___edc6e\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"field field-name-field-course-summary field-type-text-with-summary field-label-hidden\"\u003e\n\u003cdiv class=\"field-items\"\u003e\n\u003cdiv class=\"field-item even\"\u003e\n\u003cdiv class=\"card-header bg-transparent py-4 px-3\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003ch3 class=\"product_title entry-title\"\u003eMATOS Masters in Thoracic Oncology Summit 2023\u003c\/h3\u003e\n\u003cp\u003eMATOS Masters in Thoracic Oncology Summit 2023\u003c\/p\u003e\n\u003cp\u003eMeetings Events \u0026amp; Conference Coordinators Masters in Thoracic Oncology Summit 2023\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eInclude: 52 videos, size: 4.51 GB\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMATOS Masters in Thoracic Oncology Summit 2023 The \u003cstrong\u003eMasters in Thoracic Oncology Summit 2023\u003c\/strong\u003e organized by Meetings Events \u0026amp; Conference Coordinators (MECC) is a key event for professionals in the field of thoracic oncology. This summit is designed to address and discuss the current challenges and future directions in lung cancer treatment and research.\u003c\/p\u003e\n\u003ch3\u003eTarget Audience:\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eMedical, surgical, and radiation oncologists\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePulmonologists\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRadiologists\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThoracic surgeons\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePathologists\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNurse practitioners\u003c\/strong\u003e and \u003cstrong\u003enurses\u003c\/strong\u003e specializing in thoracic oncology\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eResearchers\u003c\/strong\u003e and \u003cstrong\u003eclinical scientists\u003c\/strong\u003e in the field of lung cancer\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe summit includes sessions on the latest discoveries in genetics and epigenomics, diagnosis, minimal residual disease (MRD), monitoring for recurrence, and assessment of therapeutic success with targeted therapy and immunotheray\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eALK in Front Line Therapy Second or Third Generation TKI Inhibitors What Can Help Us to Choose the Best Therapeutic Agent.mp4\u003c\/li\u003e\n\u003cli\u003eAnti-CEACAM and ROR ADCs.mp4\u003c\/li\u003e\n\u003cli\u003eBest Approaches for First Line EGFRm NSCLC.mp4\u003c\/li\u003e\n\u003cli\u003eBest Surgical Approaches for Stage III NSCLC.mp4\u003c\/li\u003e\n\u003cli\u003eBiomarkers for Perioperative Immunotherapy.mp4\u003c\/li\u003e\n\u003cli\u003eBrain Radiotherapy in Small Cell Lung Cancer When.mp4\u003c\/li\u003e\n\u003cli\u003eCellular Therapies in NSCLC Is it feasible.mp4\u003c\/li\u003e\n\u003cli\u003ectDNA Analyses in Early Detection Methylation, Proteomics and Other Efforts for Early Lung Cancer Detection.mp4\u003c\/li\u003e\n\u003cli\u003eDeciphering the Mechanism of Resistance to First Generation KRAS Inhibitors.mp4\u003c\/li\u003e\n\u003cli\u003eDeveloping New Anti-CTL4s for NSCLC Is There Any Role.mp4\u003c\/li\u003e\n\u003cli\u003eEarly Stage Resectable Lung Cancer Adjuvant Immunotherapy.mp4\u003c\/li\u003e\n\u003cli\u003eExon 20 and Uncommon EGFR Sensitive Mutations.mp4\u003c\/li\u003e\n\u003cli\u003eFrontline What are We Adding to Checkpoint Inhibitors and Chemotherapy.mp4\u003c\/li\u003e\n\u003cli\u003eFuture Challenges for lmmunotherapy in the Fight Against NSCLC.mp4\u003c\/li\u003e\n\u003cli\u003eHealth Care Disparities in Lung Cancer Genomic Profiling Has Precision Oncology Widened the Gap.mp4\u003c\/li\u003e\n\u003cli\u003eHER-3 as a New Target in NSCLC.mp4\u003c\/li\u003e\n\u003cli\u003eHER2 Tx in Advanced NSCLC From TKls to ADCs.mp4\u003c\/li\u003e\n\u003cli\u003eHow to Rescue Patients from Osimertinib Resistance.mp4\u003c\/li\u003e\n\u003cli\u003eHow to Start a Lung Cancer Screening Program.mp4\u003c\/li\u003e\n\u003cli\u003eImproving Targeted Therapies for Patients with Lung Cancers Where are the gaps and ways to fill them.mp4\u003c\/li\u003e\n\u003cli\u003eKRAS mutant NSCLC What is the Standard of Care Now.mp4\u003c\/li\u003e\n\u003cli\u003eLack of Equity in Clinical Outcomes in Blacks and Hispanics with NSCLC.mp4\u003c\/li\u003e\n\u003cli\u003eLimited Stage SCLC 2023.mp4\u003c\/li\u003e\n\u003cli\u003eManagement of LA-NSCLC in Pts with PD-L1 – 1% or Oncogenic Drivers.mp4\u003c\/li\u003e\n\u003cli\u003eMechanisms of Resistance to ALK Inhibitors.mp4\u003c\/li\u003e\n\u003cli\u003eMinimal Residual Disease as Detected by Liquid Biopsy Where are We Going.mp4\u003c\/li\u003e\n\u003cli\u003eMRD to Decide Perioperative Management in the Era of Immuno-Oncology.mp4\u003c\/li\u003e\n\u003cli\u003eNeoadjuvant Immunotherapy Position.mp4\u003c\/li\u003e\n\u003cli\u003eNovel Therapies for Thymic Malignancies.mp4\u003c\/li\u003e\n\u003cli\u003eNRG1 as a Target in NSCLC.mp4\u003c\/li\u003e\n\u003cli\u003eOptimal Management of Extensive SCLC (1st and 2nd Line).mp4\u003c\/li\u003e\n\u003cli\u003eOvercoming T-Cell Exhaustion.mp4\u003c\/li\u003e\n\u003cli\u003ePan-KRAS Inhibitors Where are We Going.mp4\u003c\/li\u003e\n\u003cli\u003ePARP Inhibitors in SCLC.mp4\u003c\/li\u003e\n\u003cli\u003ePredictive Biomarkers in Small Cell Lung Carcinoma.mp4\u003c\/li\u003e\n\u003cli\u003eRadiation Induced Immune Responses in NSCLC.mp4\u003c\/li\u003e\n\u003cli\u003eRET and NTRK The Good, The Bad, The Ugly…. and What’s Coming Up.mp4\u003c\/li\u003e\n\u003cli\u003eRole of Interleukins to Improve Efficacy of Immunotherapy.mp4\u003c\/li\u003e\n\u003cli\u003eRole of Radiotherapy in TIME Good Bad Don’t know.mp4\u003c\/li\u003e\n\u003cli\u003eROS1 and BRAf Inhibitors New Developments.mp4\u003c\/li\u003e\n\u003cli\u003eStage III Non-Surgical NSCLC Optimal Radiation Therapy Treatment Approach.mp4\u003c\/li\u003e\n\u003cli\u003eStrategies to Target Minimal Residual Disease in Lung Cancer.mp4\u003c\/li\u003e\n\u003cli\u003eSurgery for Malignant Pleural Mesothelioma.mp4\u003c\/li\u003e\n\u003cli\u003eSystemic Therapies for Mesothelioma.mp4\u003c\/li\u003e\n\u003cli\u003eThe Importance of TIME in Cancer Treatment How to Target It.mp4\u003c\/li\u003e\n\u003cli\u003eThe New Role of Microbiome in Lung Cancer Immunotherapy.mp4\u003c\/li\u003e\n\u003cli\u003eThe Role of Co-Mutations in Immunotherapy Response in NSCLC.mp4\u003c\/li\u003e\n\u003cli\u003eThe Role of SHP-2 Inhibitors Alone or in Combination.mp4\u003c\/li\u003e\n\u003cli\u003eTROP-2 and AXL as Targets in NSCLC.mp4\u003c\/li\u003e\n\u003cli\u003eUpdates in Bispecific Antibodies in NSCLC.mp4\u003c\/li\u003e\n\u003cli\u003eWhat Comes After Immunotherapy Failure in Terms of More Immunomodulation.mp4\u003c\/li\u003e\n\u003cli\u003eWhat’s After PACIFIC Can We Raise the Bar.mp4\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/header\u003e\n","brand":"My Store","offers":[{"title":"Default Title","offer_id":42954611556450,"sku":"MED-AMB07006","price":20.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Meetings-Events-Conference-Coordinators-Masters-in-Thoracic-Oncology-Summit-2023.jpg?v=1779380621","url":"https:\/\/meducourse.com\/products\/matos-masters-in-thoracic-oncology-summit-2023","provider":"Meducourse","version":"1.0","type":"link"}